A detailed history of Founders Capital Management transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Founders Capital Management holds 500 shares of GLSI stock, worth $6,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 500 -0.0%
Holding current value
$6,635
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 12, 2023

SELL
$12.12 - $20.8 $6,060 - $10,400
-500 Reduced 50.0%
500 $7,000
Q2 2022

Jul 20, 2022

BUY
$7.14 - $20.36 $7,140 - $20,360
1,000 New
1,000 $8,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $170M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Founders Capital Management Portfolio

Follow Founders Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.